echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > 15 local enterprises entering the top 20 pharmaceutical export companies to the United States, Huahai pharmaceutical industry increased by 54%

    15 local enterprises entering the top 20 pharmaceutical export companies to the United States, Huahai pharmaceutical industry increased by 54%

    • Last Update: 2017-09-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: Pharmaceutical Economic News September 15, 2017 with CFDA officially becoming an ICH member, China's drug approval system, laws and concepts continue to improve, the process of drug listing continues to strengthen, and the trend of resource integration between China and foreign countries is becoming more and more obvious Many favorable policies attract foreign enterprises to enter China and encourage more and more local pharmaceutical enterprises to go abroad In recent years, through the international exploration, the number of enterprises with the ability of internationalization of preparations is increasing, and the way to go to sea is becoming more and more diversified A number of enterprises that layout the international market in advance have gradually entered the "early harvest period" In the first half of 2017, China's import and export of Western pharmaceutical preparations exceeded US $10 billion, an increase of 26.4% year-on-year, 14.7 percentage points higher than the overall growth of foreign trade in medicine Among them, the export value was US $1548.4 million, up 0.98% year on year; the import value was US $8.49 billion, up 32.5% year on year On the one hand, it shows that, influenced by the cyclical factors of the world economy and the structural adjustment of trade, the phenomenon of weak foreign demand has not been completely changed, and the growth rate of pharmaceutical export has slowed down significantly; on the other hand, it also indicates that with the rigid growth of domestic demand and the improvement of industrial norms, various policies successively issued make the competition for Chinese market more intense One belt, one road, has a huge potential in NO.1, and the global pharmaceutical market is over 1 trillion and 100 billion US dollars in 2016 Although both developed and emerging markets are showing a growth trend, with the expiration of a large number of original research patents, the slowdown of economic growth in various countries leading to the optimization of medical expenditure and the reform of medical system, the market growth in developed countries has slowed down seriously, while the emerging markets dominated by generic drugs have grown significantly One belt, one road and one other region along the central and Eastern Europe, Central Asia and Africa, increased rapidly in the first half of this year, with an increase of 34.9%, 27.8% and 3.4% respectively One belt, one road, is India, Philippines, Pakistan, Vietnam, Burma, Russia and Poland It is also the main force to increase the export of Western medicines to the "one country along the way" Among them, one belt, one road, the other two, China has achieved more than 20% growth in India, Burma, Russia and Bangladesh, and exports to India over 70 million US dollars, and exports to Philippines, Pakistan, Thailand and Malaysia are over 30 million dollars It is the top five market for Chinese exports to the "one belt and one way" export Nigeria, Democratic Republic of Congo and Tanzania are the main driving forces for the growth of China's pharmaceutical exports to Africa in the first half of the year The export volume is over 12 million US dollars, with an increase of 10.3%, 44.6% and 60.6% respectively However, exports to several major markets such as Mali, Egypt, Madagascar, Cameroon, Uganda and South Africa declined, with exports to Cameroon, Uganda and South Africa down more than 15% year on year It is worth noting that although China's pharmaceutical exports to central and Eastern Europe and Central Asia are growing rapidly, their scale is small and they account for a small proportion of China's pharmaceutical exports, and their market potential still needs to be further explored However, Indonesia, Thailand and other ASEAN countries encouraged the localization of preparations, Peru, Venezuela and other South American countries adjusted their policies, which made it more difficult for Chinese enterprises to register, and there was instability in participating in the bidding In addition, due to the serious devaluation of local currency and the decline of payment capacity caused by the drop of oil price, the export of Chinese Western medicine preparations to these markets decreased significantly However, China has achieved significant growth in the Philippines, Vietnam, Dominica, Ecuador and other markets No.2 local enterprises have made great efforts in the European and American markets At present, the internationalization of preparations has begun to change from traditional pharmaceutical enterprises to R & D innovative pharmaceutical enterprises In recent years, almost all of China's innovative pharmaceutical enterprises have begun to implement the internationalization strategy for the European and American markets, directly facing the American market through the declaration of Anda, and gradually opening the era of combination of imitation and innovation and high-end R & D A group of enterprises with strong cost control ability, good software and hardware foundation, and rich European and American market certification experience have been born, and gradually established their own overseas sales mode, with a number of follow-up development pipeline products In the first half of this year, China's export of preparations to the United States reached 145 million US dollars, an increase of 3.5% year-on-year, accounting for 9.4% of China's total export of preparations, an increase of 0.2% year-on-year Local enterprises have become the main driving force for exports to the United States Among the top 20 enterprises exporting to the United States, 15 are local enterprises in China Huahai, Hengrui, Nantong Lianya, Qilu pharmaceutical, Renfu, etc all performed well In the first half of the year, Qilu pharmaceutical's export of preparations to the United States exceeded 6.5 million US dollars, achieving four digit growth, and became the sixth largest enterprise in China's export of preparations to the United States At present, Huahai pharmaceutical has obtained 42 anda numbers in the United States, 25 of which are listed in the United States, and many products are in the leading position in the market Through the acquisition of sulco health company (solco), the company has built its own marketing channels and formed a well-known sales platform in the industry, covering more than 95% of generic drug purchasers In the first half of this year, Huahai Pharmaceutical Co., Ltd obtained 3 anda numbers and 5 newly declared products, and its export of preparations to the United States achieved a rapid growth of 54% In the first half of the year, China's export of preparations to the EU also achieved rapid growth, with the export volume reaching 260 million US dollars, up 48.6% year on year Although China's export of preparations to the EU is still dominated by multinational enterprises such as Nordisk, AstraZeneca and Pfizer, the export of domestic enterprises to the EU has also entered a period of rapid growth, and is mainly concentrated in markets such as the UK, Germany, Spain and the Netherlands Huahai pharmaceutical has 12 products listed in 24 European countries, while Shanghai Rongheng, Shenzhen Tiandao, Anhui Hua'an, Shenzhen Zhijun, Shandong Xinhua and dongyangguang have made remarkable achievements with their channel and certification advantages The main export products to France and Denmark are antimalarial drugs and generic drugs, and they enter African markets through entrusted processing and entrepot trade No.3 export structure is further optimized High value-added products are growing rapidly In the first half of the year, the volume and price of hormones are rising There are 71 kinds of Western medicine preparations exported in China The export of high value-added products such as anti-tumor, spirit, antiviral, antihypertensive and hypolipidemic products is growing rapidly, which has become the main driving force for the export growth of preparations to Europe and the United States After last year's fall in volume and price, hormone drugs have seen a recovery growth this year, with a year-on-year growth rate of more than 36%, pushing the export volume of hormone drugs to achieve 94% growth in the first half of the year, with insulin drugs, corticosteroids and recombinant human growth hormone as the most significant growth After several years of low-speed growth, the growth rate of cephalosporin drugs picked up in the first half of this year, with a year-on-year growth of 13.4%, but the price remained low, down 4% year on year Penicillin and vitamin drugs basically maintained a steady growth trend, up 3.8% and 7% respectively year on year In contrast, anti infective drugs, which have been the main export force, have been declining against the trend, with both volume and price falling, demand in Europe, the United States and ASEAN markets falling, and excessive price pressure in India and Brazil are the main reasons In the first half of the year, the export of processing trade of Chinese Western pharmaceutical preparations reached US $700 million, a year-on-year increase of 96.3%, accounting for 45.5% of the total export of Chinese preparations, a year-on-year increase of 22 percentage points In the processing trade, the main export areas are Australia, South Korea, ASEAN, France, Belgium, India, Hong Kong and India; in the processing trade, the Chinese and foreign enterprises are equally divided, among which the export of local enterprises is mainly in the United States, Africa, Spain and other markets, while the foreign investment is mainly in Australia, Denmark and Japan 。 In contrast, the warehousing and entrepot trade in the bonded area has declined seriously in recent years, with a significant drop of 96% in the first half of the year, accounting for only 0.8% of the total export of preparations, down 19.5% year on year General trade exports fell by a small 4% year-on-year, accounting for almost the same proportion as last year No.5 overseas M & a speed up China's position in the global industrial chain With the rapid development of globalization, the division of labor in the pharmaceutical industry chain is more clear The status of Chinese pharmaceutical industry in the global industry chain is not only low-end intermediates and API suppliers More and more enterprises are actively participating in the international market competition while expanding and strengthening their business Through the layout of the whole industry chain, increasing the pace of certification and international M & A, the pharmaceutical products will be The products have entered the high-end markets in Europe and America In the first half of this year, China's enterprises were approved with 18 anda numbers in the United States, and Hengrui pharmaceutical's desflurane for inhalation was approved for listing in the United Kingdom, Germany and the Netherlands respectively The success of the first imitation of Huahai pharmaceutical's paroxetine capsule indicates that China's preparations have made another step in the field of first imitation and international certification, effectively improving the core competitiveness of the enterprise In addition, the number and scale of M & A transactions of Chinese pharmaceutical companies in regulating the market are also expanding, and the pace of international resource distribution is speeding up Through the merger and acquisition of overseas pharmaceutical enterprises, Chinese enterprises have obtained an international pharmaceutical manufacturing and registration platform, promoted the industrial upgrading of China's overall pharmaceutical manufacturing business, accelerated the internationalization process, and helped to improve the share of overseas markets, especially the standardized market Such as Fosun Pharmaceutical's acquisition of gland Pharma helps to improve the drug registration ability and talent cultivation of the whole group; humanwell's acquisition of epic not only helps to obtain multiple anda numbers, but also helps to extend its product chain and follow-up pipeline product layout; green leaf's acquisition of acino helps it to obtain its advanced TDS system of slow and controlled release, which helps it develop new dosage forms and innovative drug research and development; Huahai Charlotte plant started normal operation in the first half of the year, It has effectively penetrated the company's research, production and marketing industry chain in the United States, effectively promoted the company's entry into the drug control business and government orders in the United States, and also helped its exports to the United States continue to maintain a rapid growth trend In the first half of the year, China's pharmaceutical imports are still dominated by the EU, accounting for 71.8% of China's total pharmaceutical imports Germany, France, Italy, the United States and the United Kingdom are the top five import markets, accounting for 60% of the total import volume of preparations In addition to a small increase of 8% in imports from Italy, imports from other markets have achieved a substantial increase of more than 30% Some major import agents, such as Yongyu pharmaceutical, Keyuan Xinhai and Shanghai pharmaceutical, all increased their import business by more than 40% The expansion of domestic chemical drug market is the main driving factor of import growth In the first half of this year, China's drug terminal market reached 803.7 billion yuan, an increase of 7.8% year on year, with the largest increase in drugs of AstraZeneca, Sanofi, Bristol Myers Squibb and other enterprises
    With the acceleration of drug review and approval in China, several major imported new drugs have been published successively in the first half of this year, including antitumor drugs such as GlaxoSmithKline, bringer Ingelheim, Roche, etc., diabetes drugs of Bristol Myers Squibb and anti rheumatic drugs of Pfizer, etc the large number of approved new drugs will cause changes in the market pattern of relevant fields in China, and Drug Import will remain stable Fast growth Trend < < short cycle rebound in long cycle adjustment current global trade recovery may be in the short cycle rebound stage in long cycle adjustment, this year's medicine
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.